Ironwood Pharmaceuticals (IRWD) Q2 2024 earnings summary

Executive summary

• LINZESS prescription demand grew 11% year-over-year in Q2 2024, with new-to-brand prescriptions up 15%, marking six consecutive quarters of double-digit growth.

• Despite strong demand, higher-than-expected Medicaid utilization and related pricing headwinds led to a downward revision of full-year 2024 guidance.

• Apraglutide's phase 3 data received positive feedback, with NDA submission on track for Q1 2025 and potential commercial launch in late 2025 or early 2026.

• CMP-104 phase 2 proof-of-concept results for primary biliary cholangitis are expected in Q3 2024.

• Q2 2024 net loss was $0.9 million, a significant improvement from the prior year's $1.1 billion loss, which included a one-time IPR&D charge.

Financial highlights

• Q2 2024 revenue was $94.4 million, down 12% year-over-year, mainly due to lower LINZESS net price and collaborative revenue.

• GAAP net loss was $0.9 million; adjusted EBITDA was $28 million.

• $33 million in operating cash flow was generated in Q2 2024.

• $200 million in convertible notes repaid in June 2024, using $50 million cash and $150 million from the revolving credit facility.

• Ended Q2 2024 with $105.5 million in cash and cash equivalents.

Outlook and guidance

• FY 2024 guidance revised downward: LINZESS US net sales expected between $900 million and $950 million, with total revenue expected at $405–$425 million and adjusted EBITDA expected to exceed $120 million.

• Ironwood revenue guidance lowered to $350–$375 million; adjusted EBITDA to over $75 million, reflecting higher Medicaid utilization and pricing pressure.

• 2024 U.S. LINZESS net sales now expected to decline mid-teens percent year-over-year.

• Disciplined expense management prioritized to offset revenue headwinds.

• Focus remains on maximizing LINZESS profits and cash flows until generic entry in 2029.